Nikhil Yawalkar

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7192742/publications.pdf

Version: 2024-02-01

84	4,747	87723	102304
papers	citations	38 h-index	66 g-index

92	92	92	4422
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	European S3â€Guidelines on the systemic treatment of psoriasis vulgaris â€“ Update 2015 â€“ Short version â€“ <scp>EDF</scp> in cooperation with <scp>EADV</scp> and <scp>IPC</scp>. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 2277-2294.	1.3	353
2	Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa. Journal of the American Academy of Dermatology, 2011, 65, 790-798.	0.6	326
3	T-cell involvement in drug-induced acute generalized exanthematous pustulosis. Journal of Clinical Investigation, 2001, 107, 1433-1441.	3.9	314
4	Expression of Interleukin-12 is Increased in Psoriatic Skin. Journal of Investigative Dermatology, 1998, 111, 1053-1057.	0.3	185
5	T cell involvement in cutaneous drug eruptions. Clinical and Experimental Allergy, 2001, 31, 1398-1408.	1.4	174
6	Human T _H 9 Cells Are Skin-Tropic and Have Autocrine and Paracrine Proinflammatory Capacity. Science Translational Medicine, 2014, 6, 219ra8.	5.8	172
7	Infiltration of cytotoxic T cells in drug-induced cutaneous eruptions. Clinical and Experimental Allergy, 2000, 30, 847-855.	1.4	158
8	EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris â€“ Part 1: treatment and monitoring recommendations. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2461-2498.	1.3	149
9	Acute Generalized Exanthematous Pustulosis. American Journal of Pathology, 2002, 161, 2079-2086.	1.9	145
10	T-cell-mediated cytotoxicity against keratinocytes in sulfamethoxazol-induced skin reaction. Clinical and Experimental Allergy, 1998, 28, 1412-1417.	1.4	133
11	Acute Generalized Exanthematous Pustulosis: Pathogenesis, Genetic Background, Clinical Variants and Therapy. International Journal of Molecular Sciences, 2016, 17, 1214.	1.8	131
12	Evidence for a role for IL-5 and eotaxin in activating and recruiting eosinophils in drug-induced cutaneous eruptions. Journal of Allergy and Clinical Immunology, 2000, 106, 1171-1176.	1.5	118
13	Interleukin 23â€“Helper T Cell 17 Axis as a Treatment Target for Pityriasis Rubra Pilaris. JAMA Dermatology, 2017, 153, 304.	2.0	111
14	Toll-like receptor 2 is highly expressed in lesions of acne inversa and colocalizes with C-type lectin receptor. British Journal of Dermatology, 2008, 158, 691-697.	1.4	110
15	Canakinumab in adults with steroidâ€refractory pyoderma gangrenosum. British Journal of Dermatology, 2015, 173, 1216-1223.	1.4	95
16	Increased expression of IL-12p70 and IL-23 by multiple dendritic cell and macrophage subsets in plaque psoriasis. Journal of Dermatological Science, 2009, 54, 99-105.	1.0	93
17	Cytokines and Chemokines in Irritant Contact Dermatitis. Mediators of Inflammation, 2013, 2013, 1-7.	1.4	85
18	T Cells Isolated from Positive Epicutaneous Test Reactions to Amoxicillin and Ceftriaxone are Drug Specific and Cytotoxic. Journal of Investigative Dermatology, 2000, 115, 647-652.	0.3	84

#	Article	IF	Citations
19	EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris â€“ Part 2: specific clinical and comorbid situations. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 281-317.	1.3	84
20	Gender and age significantly determine patient needs and treatment goals in psoriasis â€“ a lesson for practice. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 700-708.	1.3	78
21	Human â€œT _H 9â€•cells are a subpopulation of PPAR-Î³ ⁺ T _H 2 cells. Science Immunology, 2019, 4, .	5.6	75
22	In vitro detection of cytotoxic T and NK cells in peripheral blood of patients with various drugâ€‘induced skin diseases. Allergy: European Journal of Allergy and Clinical Immunology, 2010, 65, 376-384.	2.7	74
23	Characterization of the cellular infiltrate during successful topical treatment of lentigo maligna with imiquimod. British Journal of Dermatology, 2004, 151, 903-906.	1.4	57
24	Drug-induced exanthems. Toxicology, 2005, 209, 131-134.	2.0	56
25	Mast cell chymase is increased in chronic atopic dermatitis but not in psoriasis. Archives of Dermatological Research, 2005, 296, 503-506.	1.1	56
26	Increased expression of the interleukinâ€‘36 cytokines in lesions of hidradenitis suppurativa. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 2091-2096.	1.3	56
27	Distinct Serum Cytokine Levels in Drugâ€“ and Measlesâ€“Induced Exanthema. International Archives of Allergy and Immunology, 1999, 120, 225-229.	0.9	52
28	Skin Manifestations of Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, and Spondyloarthritides. Clinical Reviews in Allergy and Immunology, 2017, 53, 371-393.	2.9	52
29	Swiss S1 guideline for the treatment of rosacea. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1775-1791.	1.3	50
30	Innate immune cells express IL-17A/F in acute generalized exanthematous pustulosis and generalized pustular psoriasis. Archives of Dermatological Research, 2014, 306, 933-938.	1.1	49
31	Regulatory T Cells Restrain Pathogenic T Helper Cells during Skin Inflammation. Cell Reports, 2018, 25, 3564-3572.e4.	2.9	49
32	Oral Prednisolone Induced Acute Generalized Exanthematous Pustulosis due to Corticosteroids of Group A Confirmed by Epicutaneous Testing and Lymphocyte Transformation Tests. Dermatology, 2006, 213, 40-43.	0.9	45
33	NKp46⁺ cells express granulysin in multiple cutaneous adverse drug reactions. Allergy: European Journal of Allergy and Clinical Immunology, 2011, 66, 1469-1476.	2.7	45
34	Canakinumab for Severe Hidradenitis Suppurativa. JAMA Dermatology, 2017, 153, 1195.	2.0	45
35	Elevated levels of the antimicrobial peptide <scp>LL</scp>â€37 in hidradenitis suppurativa are associated with a Th1/Th17 immune response. Experimental Dermatology, 2018, 27, 172-177.	1.4	45
36	Homozygous Missense Mutation inIL36RNin Generalized Pustular Dermatosis With Intraoral Involvement Compatible With Both AGEP and Generalized Pustular Psoriasis. JAMA Dermatology, 2015, 151, 452.	2.0	44

#	Article	IF	Citations
37	Culprit Drugs Induce Specific IL-36 Overexpression in Acute Generalized Exanthematous Pustulosis. Journal of Investigative Dermatology, 2019, 139, 848-858.	0.3	43
38	IL-17E (IL-25) Enhances Innate Immune Responses during Skin Inflammation. Journal of Investigative Dermatology, 2019, 139, 1732-1742.e17.	0.3	42
39	Apremilast in the treatment of moderate to severe hidradenitis suppurativa: A case series of 9 patients. Journal of the American Academy of Dermatology, 2017, 76, 1189-1191.	0.6	41
40	Interleukinâ€32 is highly expressed in lesions of hidradenitis suppurativa. British Journal of Dermatology, 2017, 177, 1358-1366.	1.4	40
41	Swiss S1 Guidelines on the Systemic Treatment of Psoriasis Vulgaris. Dermatology, 2016, 232, 385-406.	0.9	39
42	Increased expression of heat shock protein 90 inÂkeratinocytes and mast cells in patients with psoriasis. Journal of the American Academy of Dermatology, 2014, 70, 683-690.e1.	0.6	34
43	Effects of Omalizumab on FcÎµRI and IgE Expression in Lesional Skin of Bullous Pemphigoid. Frontiers in Immunology, 2019, 10, 1919.	2.2	32
44	New onset of mainly guttate psoriasis after COVIDâ€19 vaccination: a case report. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e752-e755.	1.3	31
45	Immunohistology of drug-induced exanthema: clues to pathogenesis. Current Opinion in Allergy and Clinical Immunology, 2001, 1, 299-303.	1.1	28
46	Down-regulation of IL-12 by topical corticosteroids in chronic atopic dermatitis. Journal of Allergy and Clinical Immunology, 2000, 106, 941-947.	1.5	27
47	Prognostic markers in lentigo maligna patients treated with imiquimod cream: A long-term follow-up study. Journal of the American Academy of Dermatology, 2016, 74, 81-87.e1.	0.6	27
48	Acute generalized exanthematous pustulosis associated with ipilimumab and nivolumab. Journal of the European Academy of Dermatology and Venereology, 2018, 32, e256-e257.	1.3	27
49	Elevated serum levels of interleukins 5, 6, and 10 in a patient with drug-induced exanthem caused by systemic corticosteroids. Journal of the American Academy of Dermatology, 1998, 39, 790-793.	0.6	25
50	Nanoparticle-Coupled Topical Methotrexate Can Normalize Immune Responses and Induce Tissue Remodeling in Psoriasis. Journal of Investigative Dermatology, 2020, 140, 1003-1014.e8.	0.3	25
51	Generalized Comedones, Acne, and Hidradenitis Suppurativa in a Patient with an FGFR2 Missense Mutation. Frontiers in Medicine, 2017, 4, 16.	1.2	24
52	Pathogenesis of Drug-Induced Exanthema. International Archives of Allergy and Immunology, 2001, 124, 336-338.	0.9	23
53	Safety and Efficacy of Methotrexate for Chinese Adults With Psoriasis With and Without Psoriatic Arthritis. JAMA Dermatology, 2019, 155, 327.	2.0	19
54	IgE and FcÎµ <scp>RI</scp> are highly expressed on innate cells in psoriasis. British Journal of Dermatology, 2016, 175, 122-133.	1.4	17

#	Article	IF	Citations
55	Topical Treatment of Psoriasis Vulgaris: The Swiss Treatment Pathway. Dermatology, 2021, 237, 166-178.	0.9	17
56	Adalimumab in Recalcitrant Severe Psoriasis Associated with Atopic Dermatitis. Case Reports in Dermatology, 2013, 5, 332-335.	0.3	15
57	<scp>TT</scp> genotype of rs10036748 in <scp>TNIP</scp> 1 shows better response to methotrexate in a Chinese population: a prospective cohort study. British Journal of Dermatology, 2019, 181, 778-785.	1.4	15
58	Apremilast for treatment of recalcitrant aphthous stomatitis. JAAD Case Reports, 2017, 3, 410-411.	0.4	14
59	Apremilast in Treatment-Refractory Recurrent Aphthous Stomatitis. New England Journal of Medicine, 2019, 381, 1975-1977.	13.9	14
60	Rapid Downregulation of Innate Immune Cells, Interleukin-12 and Interleukin-23 in Generalized Pustular Psoriasis with Infliximab in Combination with Acitretin. Dermatology, 2012, 225, 338-343.	0.9	13
61	International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis. JAMA Dermatology, 2022, 158, 561.	2.0	12
62	CD1a-positive dendritic cells transport the antigen DNCB intracellularly from the skin to the regional lymph nodes in the induction phase of allergic contact dermatitis. Archives of Dermatological Research, 2001, 293, 420-426.	1.1	11
63	Maculopapular Drug Eruptions. , 2007, , 242-250.		11
64	Effectiveness of methotrexate in moderate to severe psoriasis patients: real-world registry data from the Swiss Dermatology Network for Targeted Therapies (SDNTT). Archives of Dermatological Research, 2019, 311, 753-760.	1.1	11
65	Long-Term Effectiveness and Drug Survival of Apremilast in Treating Psoriasis: A Real-World Experience. Dermatology, 2022, 238, 267-275.	0.9	10
66	Hypothesis-free analyses from a large psoriatic arthritis cohort support merger to consolidated peripheral arthritis definition without subtyping. Clinical Rheumatology, 2017, 36, 2035-2043.	1.0	8
67	Infliximab reduces activated myeloid dendritic cells, different macrophage subsets and CXCR 3â€positive cells in granuloma annulare. Journal of Dermatology, 2019, 46, 808-811.	0.6	8
68	The Impact of ANxA6 Gene Polymorphism on the Efficacy of Methotrexate Treatment in Psoriasis Patients. Dermatology, 2021, 237, 579-587.	0.9	8
69	Identification of proteins associated with development of psoriatic arthritis in peripheral blood mononuclear cells: a quantitative iTRAQ-based proteomics study. Journal of Translational Medicine, 2021, 19, 331.	1.8	8
70	DRUG HYPERSENSITIVITY. Acta Clinica Belgica, 2009, 64, 529-533.	0.5	7
71	Ixekizumab for treatment of refractory acute generalized exanthematous pustulosis caused by hydroxychloroquine. JAAD Case Reports, 2020, 6, 634-636.	0.4	7
72	<scp>iTRAQ</scp>â€based quantitative proteomics reveals biomarkers/pathways in psoriasis that can predict the efficacy of methotrexate. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 1784-1795.	1.3	6

#	Article	IF	Citations
73	Successful treatment of refractory folliculitis decalvans with apremilast. JAAD Case Reports, 2020, 6, 1079-1081.	0.4	5
74	Interleukin-17E, inducible nitric oxide synthase and arginase1 as new biomarkers in the identification of neutrophilic dermatoses. Clinical and Experimental Dermatology, 2022, 47, 675-683.	0.6	5
75	The difference of lipid profiles between psoriasis with arthritis and psoriasis without arthritis and sex-specific downregulation of methotrexate on the apolipoprotein B/apolipoprotein A-1 ratio. Arthritis Research and Therapy, 2022, 24, 17.	1.6	5
76	MTHFR Gene Polymorphism Association With Psoriatic Arthritis Risk and the Efficacy and Hepatotoxicity of Methotrexate in Psoriasis. Frontiers in Medicine, 2022, 9, 869912.	1.2	5
77	Characterization of dendritic cells and macrophages in irritant contact dermatitis. Journal of Dermatological Science, 2010, 57, 216-218.	1.0	4
78	IgA Triggers Cell Death of Neutrophils When Primed by Inflammatory Mediators. Journal of Immunology, 2020, 205, 2640-2648.	0.4	4
79	Enhanced Pro-apoptotic Effects of Fe(II)-Modified IVIG on Human Neutrophils. Frontiers in Immunology, 2020, 11, 973.	2.2	4
80	TineÐ° Corporis with Trichophyton Rubrum Mimicking a Flare-Up of Psoriasis UnderTreatment with IL17-Inhibitor Ixekizumab. Case Reports in Dermatology, 2021, 13, 347-351.	0.3	4
81	New onset of sarcoidosis after <scp>COVID</scp>â€19 infection. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	1.3	4
82	Linkage between patientsâ€™ characteristics and prescribed systemic treatments for psoriasis: a semantic connectivity map analysis of the Swiss Dermatology Network for Targeted Therapies registry. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 2313-2318.	1.3	2
83	Herpetiform aphthous ulcerations induced by secukinumab: Report of 2 cases. JAAD Case Reports, 2020, 6, 1107-1109.	0.4	1
84	Sex-differential downregulation of methotrexate on plasma viscosity and whole blood viscosity in psoriasis. Clinical Hemorheology and Microcirculation, 2022, , 1-10.	0.9	0